In a Nutshell
Researchers have developed a blood panel comprising 19 proteins that could help predict whether individuals carrying an ALS gene will develop the disease within six months to five years. This panel outperformed the current leading marker, NEFL, in most tested time frames.
The new blood test estimates the onset of symptoms with an average error of about 1.6 years, compared to 2.4 years for NEFL alone. Notably, many of the proteins in this panel relate more to muscle function than nerve damage, suggesting that muscle-related changes might start earlier than previously thought.
For families with a genetic link to ALS, the uncertainty of when symptoms will emerge can be incredibly distressing. Now, it appears that a simple blood test could potentially give insight into which carriers might develop the disease and when, well before any noticeable symptoms appear.
A study reported in Nature Medicine identified 19 proteins in blood plasma that together can predict whether a gene carrier will develop ALS. This transition from being a carrier to exhibiting symptoms is termed phenoconversion. The panel was tested over various intervals, estimating the time until symptom onset with a notable average error margin. However, researchers caution that this test isn’t quite ready for clinical use just yet; it needs further validation and should be assessed with more widely available lab methods.
ALS, known as Lou Gehrig’s disease, is a progressive and deadly condition that affects the nerve cells responsible for movement. There is no cure, and treatment options are limited. Recently, there’s been a growing awareness that intervening before symptoms appear might be key to effective treatments. Until now, however, doctors had very few reliable ways to predict which gene carriers would actually develop the disease and when.
How the Study Was Conducted
This research drew on approximately 18 years of data from the Pre-Symptomatic Familial ALS (Pre-fALS) study, which monitored individuals with known ALS gene variants, looking at changes before and after disease onset. The analysis involved 516 blood samples from 137 participants across different categories: 33 who eventually developed ALS, 35 already diagnosed, 10 carriers without symptoms, and 59 healthy controls.
A single method assessed over 5,400 proteins in each blood sample, finding around 5,300 suitable for analysis. Researchers observed how protein levels fluctuated in carriers before symptoms emerged, comparing results with healthy controls. Among these proteins, 137 displayed significant variations between ALS patients and healthy individuals, and 92 altered in the blood prior to symptom onset. A series of predictive models, including machine learning techniques, identified the optimal protein combinations for forecasting who would develop ALS and when.
A Robust Blood Panel
Historically, NEFL has been the primary blood marker indicating pre-symptomatic ALS, as its levels surge just prior to symptom onset. It currently serves as a foundation in the ongoing ATLAS trial aimed at preventing ALS onset in gene carriers.
Though NEFL remains the most valuable individual marker, the 19-protein panel proved more effective than NEFL alone in most situations assessed. For example, within a one-year forecast, the panel achieved an accuracy score of 0.889, while NEFL stood at 0.775. Even at the five-year mark, the panel outperformed NEFL, holding a score of 0.802 compared to NEFL’s 0.712. Interestingly, NEFL came close to matching the full panel’s predictions only for the six-month window, likely due to its drastic rise just before symptom onset.
An important observation is that many proteins in the panel aren’t even related to nerve damage; instead, they are linked to muscle biology encompassing structure, maintenance, and degradation aspects. Muscle-wasting proteins increased in the blood well before symptoms appeared, indicating that muscle deterioration could begin significantly earlier than had been previously acknowledged.
What the Test Reveals about Onset Timing
Apart from predicting who might develop ALS, the study sought to forecast when this would occur. Utilizing data solely from the 33 individuals who eventually developed the disease, the 19-protein panel predicted the time to phenoconversion with an average error of 1.6 years, as opposed to NEFL’s 2.4 years.
This is crucial for designing clinical trials. If researchers can approximate when a gene carrier will experience symptoms, they can tailor trials accordingly. For example, to design a trial for individuals forecasted to show symptoms within two years, a follow-up of around 3.6 years would be practical, based on findings from the ATLAS trial.
To validate these results across a broader scope, researchers applied data from the UK Biobank, a large database with genetic information and blood samples from numerous participants. This was more complicated, as they had to estimate symptom onset retroactively from hospital records. While this added some uncertainty, preliminary observations suggested some consistency with initial findings: several critical proteins were elevated before symptoms, and once again, the multi-protein panel surpassed NEFL in predicting timing.
Future Directions for Early Detection
Researchers emphasize that while these findings are promising, further validation is essential. The primary dataset, with its extensive pre-symptomatic information, involved a relatively small cohort, mainly consisting of individuals with specific genetic backgrounds. It remains to be seen if the panel performs similarly well across a more diverse group, including those who develop ALS without known genetic links.
Additionally, an important obstacle is the technology used in this study. The specialized equipment employed isn’t a standard clinical tool, preventing immediate application in routine medical settings.
Nonetheless, the notion of anticipating who may develop ALS and when, years prior to any observable symptoms, is a significant advancement. The pressing question now is how quickly these insights can translate into preventive treatments for the disease.
